# Statins to Prevent Cancer Associated Blood Clots

Study · id `cardio:ct-nct07303816` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07303816](<https://clinicaltrials.gov/study/NCT07303816>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07303816

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 4000 participants.

## Technical summary

Registry record NCT07303816. Randomized; triple masking; primary purpose prevention. Start 2026-06-11 (actual); primary completion 2031-03-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 4000 participants (planned count; ClinicalTrials.gov record NCT07303816, source copy `cardio:ctgov-nct07303816-2026-09-16`, retrieved 2026-10-31)
- Started: 2026-06-11 (actual) (ClinicalTrials.gov record NCT07303816, source copy `cardio:ctgov-nct07303816-2026-09-16`, retrieved 2026-10-31)
- Primary completion: 2031-03-31 (anticipated) (ClinicalTrials.gov record NCT07303816, source copy `cardio:ctgov-nct07303816-2026-09-16`, retrieved 2026-10-31)
- Completion: 2032-03-31 (anticipated) (ClinicalTrials.gov record NCT07303816, source copy `cardio:ctgov-nct07303816-2026-09-16`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT07303816, source copy `cardio:ctgov-nct07303816-2026-09-16`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07303816-2026-09-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: Statins to Prevent Cancer Associated Blood Clots
- Acronym: STAT-CAT
- Condition: Venous Thromboembolism
- Condition: Cancer
- Condition: Cardiovascular Events
- Intervention (Drug): Rosuvastatin
- Intervention (Drug): Placebo Drug
- Lead sponsor: Brigham and Women's Hospital
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH
- Collaborator: Dana-Farber/Brigham and Women's Cancer Center
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)
- Registry lists this organization as the lead sponsor: Brigham and Women's Hospital (`cardio:org-brigham-and-women-s-hospital`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

## Provenance

Content hash: 1a45b5b0716013e06df25de53a3a6b2bbd93435f32500f12d6f7b64682f757df
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
